The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
REGULATORY
Japan Approves Moderna Vaccine for COVID-19 Booster
Japan’s health ministry granted special emergency approval for Moderna’s COVID-19 vaccine for its use as a booster, or the third shot for people who have received a primary course of two doses. The nod comes just a day after the…
To read the full story
Related Article
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- Shorter Booster Interval for All Citizens Difficult: Health Minister
December 8, 2021
- Japan Mulls Shortener Interval for Boosters amid Omicron Fears
December 2, 2021
- Health Minister Stresses Basic 8-Month Interval for Booster Shot
November 17, 2021
- Japan to Use mRNA Jabs for Boosters, Pfizer Vaccine for Time Being: Panel
November 16, 2021
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
- Japan Panel OKs Booster Shots for All People Who Took 2 Doses
October 29, 2021
- MHLW Eyes Booster Shots for Healthcare Workers from December
September 24, 2021
- Japan Needs Setups to Execute Booster Shots by Year-End: Minister
September 22, 2021
- Japan to Offer COVID-19 Booster Shots, Targets to Be Discussed Later
September 21, 2021
- MHLW to Promptly Seek Expert Panel Discussion on Booster Shots: Minister
September 13, 2021
- Japan Should Arrange Boosters Immediately, Mix-and-Match Doses Too: LDP
September 10, 2021
- COVID-19 Expert Omi Urges Govt to Consider Booster Shots
September 9, 2021
REGULATORY
- Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- PMDA Reviewing New Safety Risks for Opdivo, Keytruda and More
May 23, 2022
- MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
- Sanofi’s CAD Therapy Sutimlimab Up for PAFSC Review on June 2
May 20, 2022
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…